ATE321452T1 - Tetracycline verbindungen zur behandlung von spezifischen krebsarten - Google Patents

Tetracycline verbindungen zur behandlung von spezifischen krebsarten

Info

Publication number: ATE321452T1
Authority: AT; Austria
Prior art keywords: cancer; cells; growth; tetracycline compounds; treatment
Prior art date: 1997-01-15

Application number

AT98902437T

Other languages

English (en)

Inventor

Lorne M Golub

Thomas F Mcnamara

Nungavaram S Ramamurthy

Hsi-Ming Lee

Sanford Simon

Balakrishna L Lokeshwar

Marie G Selzer

Normal L Block

Original Assignee

Univ New York State Res Found

Univ Miami

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-15

Filing date

1998-01-15

Publication date

2006-04-15

1998-01-15 Application filed by Univ New York State Res Found, Univ Miami filed Critical Univ New York State Res Found

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE321452T1 publication Critical patent/ATE321452T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
-1 TETRACYCLINE COMPOUNDS Chemical class 0.000 title abstract 2
239000004098 Tetracycline Substances 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
229960002180 tetracycline Drugs 0.000 title abstract 2
229930101283 tetracycline Natural products 0.000 title abstract 2
235000019364 tetracycline Nutrition 0.000 title abstract 2
206010027476 Metastases Diseases 0.000 abstract 2
230000005907 cancer growth Effects 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
230000009401 metastasis Effects 0.000 abstract 2
NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
208000029742 colonic neoplasm Diseases 0.000 abstract 1
230000003013 cytotoxicity Effects 0.000 abstract 1
231100000135 cytotoxicity Toxicity 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
201000005202 lung cancer Diseases 0.000 abstract 1
208000020816 lung neoplasm Diseases 0.000 abstract 1
201000001441 melanoma Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT98902437T 1997-01-15 1998-01-15 Tetracycline verbindungen zur behandlung von spezifischen krebsarten ATE321452T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/783,655 US5837696A (en)	1997-01-15	1997-01-15	Method of inhibiting cancer growth

Publications (1)

Publication Number	Publication Date
ATE321452T1 true ATE321452T1 (de)	2006-04-15

Family

ID=25130005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98902437T ATE321452T1 (de)	1997-01-15	1998-01-15	Tetracycline verbindungen zur behandlung von spezifischen krebsarten

Country Status (11)

Country	Link
US (2)	US5837696A (de)
EP (1)	EP0971585B1 (de)
JP (1)	JP4428727B2 (de)
KR (1)	KR20000070212A (de)
AT (1)	ATE321452T1 (de)
AU (1)	AU729886B2 (de)
CA (1)	CA2277865C (de)
DE (1)	DE69834024T2 (de)
ES (1)	ES2262221T3 (de)
PT (1)	PT971585E (de)
WO (1)	WO1998031224A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5837696A (en) *	1997-01-15	1998-11-17	The Research Foundation Of State University Of New York	Method of inhibiting cancer growth
US6429204B1 (en)	1997-01-15	2002-08-06	University Of Miami	Method of inhibiting cancer growth
DK1041991T3 (da) *	1997-12-19	2008-07-28	Univ New York	Ikke-antibakterielle tetracycliner til behandling af multipel sklerose
US6277061B1 (en) *	1998-03-31	2001-08-21	The Research Foundation Of State University Of New York	Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) *	1998-09-11	2000-01-18	The Research Foundation Of State University Of New York	Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) *	1998-09-21	1999-11-02	The Research Foundation Of State University Of New York	Method of preventing acute lung injury
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CN1398189A (zh) *	1998-12-23	2003-02-19	G.D.西尔公司	用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
US6984619B1 (en) *	1999-03-19	2006-01-10	Arch Development Corporation	Method for protection against tumor metastasis formation
DE10032256C2 (de) *	2000-07-03	2003-06-05	Infineon Technologies Ag	Chip-ID-Register-Anordnung
AU2002256092C1 (en) *	2001-04-05	2009-10-15	Collagenex Pharmaceuticals, Inc.	Controlled delivery of tetracycline compounds and tetracycline derivatives
JP2004537544A (ja)	2001-07-13	2004-12-16	パラテックファーマシューティカルズインコーポレイテッド	標的治療活性を有するテトラサイクリン化合物
US20060194773A1 (en) *	2001-07-13	2006-08-31	Paratek Pharmaceuticals, Inc.	Tetracyline compounds having target therapeutic activities
CA2462572C (en) *	2001-10-05	2008-11-18	Tetragenex Pharmaceuticals, Inc.	Tetracycline derivatives and methods of use thereof
PE20030701A1 (es) *	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
ES2551708T3 (es)	2002-01-08	2015-11-23	Paratek Pharmaceuticals, Inc.	Compuestos de 4-desdimetilamino tetraciclina
EP1482926A4 (de)	2002-03-08	2006-04-12	Paratek Pharm Innc	Amino-methyl-substituierte tetracyclin-verbindungen
WO2003079984A2 (en)	2002-03-21	2003-10-02	Paratek Pharmaceuticals, Inc.	Substituted tetracycline compounds
KR20050005466A (ko) *	2002-05-06	2005-01-13	콜라제넥스 파마슈티칼스, 인크	점막염 및 진균 감염을 동시에 치료하는 방법
JP2005533766A (ja) *	2002-05-20	2005-11-10	コッラジェネックスファーマシューチカルスインコーポレイテッド	アレルギー反応の治療方法
EA200900540A1 (ru)	2002-07-12	2009-12-30	Пэрэтек Фамэсьютикэлс, Инк.	Замещённые соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
CA2503446C (en) *	2002-10-24	2012-12-18	Paratek Pharmaceuticals, Inc.	Methods of using substituted tetracycline compounds to modulate rna
CA2894736C (en)	2003-04-07	2019-07-16	Supernus Pharmaceuticals, Inc.	Once daily formulations of tetracyclines
EP1648859B1 (de)	2003-07-09	2013-02-27	Paratek Pharmaceuticals, Inc.	Substituierte tetracyclinverbindungen
JP4738333B2 (ja)	2003-07-09	2011-08-03	パラテックファーマシューティカルズインコーポレイテッド	９−アミノメチルテトラサイクリン化合物のプロドラッグ
US7786099B2 (en) *	2004-01-15	2010-08-31	Paratek Pharmaceuticals, Inc.	Aromatic a-ring derivatives of tetracycline compounds
EP2269991A3 (de)	2004-10-25	2011-09-21	Paratek Pharmaceuticals, Inc.	Substituierte Tetracyclinverbindungen
WO2006047671A2 (en)	2004-10-25	2006-05-04	Paratek Pharmaceuticals, Inc.	4-aminotetracyclines and methods of use thereof
JP2009502809A (ja) *	2005-07-21	2009-01-29	パラテックファーマシューティカルズインコーポレイテッド	１０−置換テトラサイクリンおよびその使用方法
EP2450347B1 (de)	2006-12-21	2015-06-24	Paratek Pharmaceuticals, Inc.	Tetracyxlin-Derivate zur Behandlung bakterieller, viraler und parasitärer Infektionen
PT2120963T (pt) *	2006-12-21	2018-12-17	Paratek Pharm Innc	Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele
JP2010525069A (ja) *	2007-04-27	2010-07-22	パラテックファーマシューティカルズインコーポレイテッド	アミノアルキルテトラサイクリン化合物の合成方法および精製方法
BRPI0813990A2 (pt) *	2007-07-06	2011-09-13	Paratek Pharmaceuticals, Inc.	métodos para sintetizar compostos de minociclina substituìda
TWI680117B (zh)	2008-05-19	2019-12-21	派洛泰克藥物股份有限公司	四環素化合物之甲苯磺酸鹽及同素異形體
ES2558512T3 (es)	2008-08-08	2016-02-04	Tetraphase Pharmaceuticals, Inc.	Compuestos de tetraciclina sustituida con C7-fluoro
WO2010129057A2 (en)	2009-05-08	2010-11-11	Tetraphase Pharmaceuticals, Inc.	Tetracycline compounds
HUE037852T2 (hu)	2009-08-28	2018-09-28	Tetraphase Pharmaceuticals Inc	Tetraciklin-vegyületek
EP2544692A4 (de) *	2010-03-10	2013-08-07	Univ Health Network	Verwendung von tigecyclin zur behandlung von krebs
JP5820462B2 (ja)	2010-03-31	2015-11-24	テトラフェースファーマシューティカルズ，インコーポレイテッド	多環式テトラサイクリン化合物
SMT201900096T1 (it)	2012-08-31	2019-02-28	Tetraphase Pharmaceuticals Inc	Composti di tetracicline
CN105142631A (zh) *	2013-01-14	2015-12-09	健康诊所有限公司	抗癌药物和用途
MA46567A (fr)	2016-10-19	2019-08-28	Tetraphase Pharmaceuticals Inc	Formes cristallines de l'éravacycline
WO2018195434A1 (en)	2017-04-21	2018-10-25	Lisanti Michael P	Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018195446A1 (en)	2017-04-21	2018-10-25	Lisanti Michael P	Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018213764A1 (en)	2017-05-19	2018-11-22	Lunella Biotech, Inc.	Companion diagnostics for mitochondrial inhibitors
US11160821B2 (en)	2017-05-19	2021-11-02	Lunella Biotech, Inc.	Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2020097450A1 (en)	2018-11-09	2020-05-14	Tetraphase Pharmaceuticals, Inc.	Polymorphic forms of a compound and uses thereof
CN115006411A (zh) *	2022-07-26	2022-09-06	中南大学湘雅医院	依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5308839A (en) *	1989-12-04	1994-05-03	The Research Foundation Of State University Of New York	Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) *	1989-12-04	2000-03-06	ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク	非ステロイド抗炎症剤及びテトラサイクリンの配合
WO1992012717A2 (en) *	1991-01-15	1992-08-06		A composition containing a tetracycline and use for inhibiting angiogenesis
US5668122A (en) *	1993-07-28	1997-09-16	Fife; Rose S.	Method to treat cancer with tetracyclines
US5574026A (en) *	1994-12-13	1996-11-12	American Cyanamid Company	Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5567693A (en) *	1994-12-13	1996-10-22	American Cyanamid Company	Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5563130A (en) *	1994-12-13	1996-10-08	American Cyanamid Company	Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5837696A (en) *	1997-01-15	1998-11-17	The Research Foundation Of State University Of New York	Method of inhibiting cancer growth

1997
- 1997-01-15 US US08/783,655 patent/US5837696A/en not_active Expired - Lifetime
1998
- 1998-01-15 WO PCT/US1998/000332 patent/WO1998031224A1/en not_active Ceased
- 1998-01-15 AU AU59104/98A patent/AU729886B2/en not_active Ceased
- 1998-01-15 US US09/007,645 patent/US6100248A/en not_active Expired - Lifetime
- 1998-01-15 KR KR1019997006438A patent/KR20000070212A/ko not_active Ceased
- 1998-01-15 ES ES98902437T patent/ES2262221T3/es not_active Expired - Lifetime
- 1998-01-15 EP EP98902437A patent/EP0971585B1/de not_active Expired - Lifetime
- 1998-01-15 CA CA002277865A patent/CA2277865C/en not_active Expired - Fee Related
- 1998-01-15 PT PT98902437T patent/PT971585E/pt unknown
- 1998-01-15 AT AT98902437T patent/ATE321452T1/de active
- 1998-01-15 DE DE69834024T patent/DE69834024T2/de not_active Expired - Lifetime
- 1998-01-15 JP JP53443498A patent/JP4428727B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0971585B1 (de)	2006-03-29
JP4428727B2 (ja)	2010-03-10
EP0971585A4 (de)	2001-01-24
JP2001508794A (ja)	2001-07-03
DE69834024D1 (de)	2006-05-18
ES2262221T3 (es)	2006-11-16
AU729886B2 (en)	2001-02-15
WO1998031224A1 (en)	1998-07-23
US6100248A (en)	2000-08-08
EP0971585A1 (de)	2000-01-19
DE69834024T2 (de)	2006-12-07
AU5910498A (en)	1998-08-07
CA2277865C (en)	2009-06-02
CA2277865A1 (en)	1998-07-23
PT971585E (pt)	2006-08-31
KR20000070212A (ko)	2000-11-25
US5837696A (en)	1998-11-17

Legal Events

Date

Code

Title

Description

2007-01-15

UEP

Publication of translation of european patent specification

Ref document number: 0971585

Country of ref document: EP

Publication	Publication Date	Title
DE69834024D1 (de)	2006-05-18	Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69830072D1 (de)	2005-06-09	Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE368466T1 (de)	2007-08-15	Androgensyntheseinhibitoren
MX9804009A (es)	1998-11-29	Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
YU596A (sh)	1998-12-23	Estrogen agonisti/antagonisti
DE60035204D1 (de)	2007-07-26	Tyrosinderivate
ATE415979T1 (de)	2008-12-15	Behandlung mit anti-erbb2 antikörpern
DE60015070D1 (de)	2004-11-25	Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ZA988826B (en)	1999-03-29	Acylsulfamoylbenzamides crop protection compositions comprising them and processes for their preparation
DE60033658D1 (de)	2007-04-12	Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE208210T1 (de)	2001-11-15	Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
ATE316785T1 (de)	2006-02-15	Jak-3 hemmer zur behandlung von allergischen störungen
ATE313326T1 (de)	2006-01-15	VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
DE602004015811D1 (de)	2008-09-25	Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
TR200001012T2 (tr)	2000-09-21	Yeni ariloksi-alkil-dialkilaminler.
HUP0104688A2 (hu)	2002-03-28	Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
DE60021381D1 (de)	2005-08-25	Chinonverbindungen zur behandlung von krankheiten
DE69932864D1 (de)	2006-09-28	Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
BR0008788A (pt)	2001-11-06	Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
DE69902523D1 (de)	2002-09-19	Verwendung von erythropoietin zur behandlung von multiple myelom
ATE190352T1 (de)	2000-03-15	Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69921130D1 (de)	2004-11-18	Verfahren und stoffe zur behandlung des prostatakarzinomes
TR199800243T1 (xx)	1998-06-22	Prolil endopeptidaz inhibit�rleri.
ATE411036T1 (de)	2008-10-15	Verwendung von aplidine in der behandlung von pankreaskrebs
ATE423129T1 (de)	2009-03-15	Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs